Search | Clinical Trials Finder

Conditions: Breast Cancer, Obesity
Interventions: Exercise; Behavioral
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Target Drug-related Adverse Events
Interventions: Urine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results; Other
Lead sponsor: InSource Diagnostics; Industry
Eligibility: 12 Years and older
Enrollment: 14,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 1
States / cities: Tazewell, Tennessee

Conditions: Coronary Artery Stenosis
Interventions: State-of-the-Art Percutaneous Coronary Intervention, standard CABG; Procedure
Lead sponsor: Duk-Woo Park, MD; Other
Eligibility: 20 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Non-Small-Cell Lung Cancer
Interventions: Amivantamab, Lazertinib, Carboplatin, Pemetrexed; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 17
States / cities: Duarte, California • La Jolla, California • Orange, California + 14 more

Conditions: Conduct Disorder, Oppositional Defiant Disorder
Interventions: Reward-Emphasized Treatment, Standard Treatment; Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 7 Years to 12 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Spondylolysis, Symptomatic Spondylolysis, Athletes
Interventions: Bone Stimulator, Standard of Care Spondylolysis Treatment; Device · Other
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 16 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Probiotic, Therapeutic Conventional Surgery; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Colitis, Ulcerative
Interventions: Combined Anti-inflammatory Diet (CAID); Behavioral
Lead sponsor: Transparency Life Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Brookline, Massachusetts

Conditions: Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
Interventions: iC9-CAR19 cells, Rimiducid, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 3 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2037
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hepatitis C, Medication Adherence
Interventions: Intensive Models (mDOT and CGT) of HCV Care; Other
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Type 2 Diabetes Mellitus
Interventions: Device: Omnipod M System with study CGM, Standard Therapy plus study CGM; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 27
States / cities: Los Angeles, California • Newport Beach, California • Santa Barbara, California + 23 more

Conditions: Tibia Fracture
Interventions: Ibuprofen; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Locally Advanced or Metastatic Solid Tumors
Interventions: PTT-936, Combination of PTT-936 and anti-PD-1/L1 therapy; Drug
Lead sponsor: Pyrotech Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Beverly Hills, California • Margate, Florida • San Antonio, Texas

Conditions: Patent Ductus Arteriosus
Interventions: optimized ibuprofen, Standard Ibuprofen; Drug
Lead sponsor: OSF Healthcare System; Other
Eligibility: 1 Day to 29 Days
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Pleural Effusion, Malignant
Interventions: Standard Drainage Instructions, Aggressive Drainage Instructions; Other
Lead sponsor: Duke University; Other
Eligibility: 19 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone; Device · Drug
Lead sponsor: Diane George; Other
Eligibility: Up to 22 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Methicillin-Resistant Staphylococcus Aureus, Recurrence, Staphylococcal Skin Infections, Antibiotic Resistance
Interventions: 2% mupirocin ointment, Chlorhexidine wash, Hygiene protocol; Drug · Other · Behavioral
Lead sponsor: Clinical Directors Network; Network
Eligibility: 7 Years to 70 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Brooklyn, New York • New York, New York • The Bronx, New York

Conditions: Thalassemia Major
Interventions: DST-0509, Jadenu, Exjade; Drug
Lead sponsor: DisperSol Technologies, LLC; Industry
Eligibility: 8 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Appendicitis (Diagnosis)
Interventions: Cefoxitin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes Mellitus, Type 2, Medication Adherence
Interventions: UMS Strategy, SMS Text Messaging; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Healthy Adults
Interventions: PF-07220060, Carbamazepine ER Tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Medication Adherence, Kidney Transplant
Interventions: mHealth Intervention; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 14 Years to 21 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anterior Cruciate Ligament Reconstruction
Interventions: Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions, Surgical technique: Transphyseal reconstruction, Surgical technique: Partial transphyseal reconstruction, Surgical technique: Physeal sparing reconstruction by the Anderson method, Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method; Other · Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 18 Years
Enrollment: 765 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2030
U.S. locations: 10
States / cities: Palo Alto, California • San Diego, California • Atlanta, Georgia + 7 more

Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 136
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 94 more

Search by objective public record fields.

Exercise in Breast Cancer Survivors

Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens

Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits

Bone Stimulator for Spondylolysis

Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer

Decentralized Dietary UC Pilot Trial

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Intensive Models of HCV Care for Injection Drug Users

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates

Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

Precision Antibiotic Dosing for Appendectomy

Regimen Education and Messaging in Diabetes (REMinD)

A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060

A Pilot Study of mDOT for Immunosuppressant Adherence in Adolescent Kidney Transplant Recipients

Pediatric ACL: Understanding Treatment Options

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial